Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 39; no. 6; p. 485
• Main Authors: Cao, Y W, Shi, Q, Zhang, M C, Xu, P P, Chen, S, Zhao, W L, Wang, L
• Format: Journal Article
• Language: Chinese
• Published: China 14.06.2018
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Prednisone; Prognosis; Treatment Outcome; Vincristine; Tumor burden; Lymphoma, large B-cell, diffuse; Antineoplastic combined chemotherapy protocols; Prognosis
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2018.06.010

To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. A total of 87 newly diagnosed DLBCL patients who received RCDOP regimen from October 2012 to October 2017 were enrolled into this study. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test, and (2) tests were used for categorical data. Among the 87 DLBCL patients treated with RCDOP regimen, 81 patients achieved complete remission (CR) or partial remission (PR), with ORR as 93.1%. Patients were further classified into groups, according to the risk factors, such as IPI scores, multiple extra-nodal involvement, bulky disease, age>60, tumor Ki-67>80%, elevated serum LDH level and advanced Ann Arbor stage. The progression-free survival (PFS, =0.084) and overall survival (OS, =0.515) had no statistic